Stocks
Barclays Maintains Buy Rating on Eli Lilly & Co with $1,400 Price Target
Barclays analyst Emily Field has maintained her 'Buy' rating on Eli Lilly & Co (LLY) and set a price target of $1,400.00.
Field's average return on recommended stocks is 2.0%, with a success rate of 45.91%. She covers the Healthcare sector for Barclays and focuses on companies like LLY, Merck & Company, and Amgen.
In addition to Field's report, Eli Lilly & Co has also received a 'Buy' rating from Guggenheim's Seamus Fernandez in his September 17 report. However, on September 10, HSBC maintained a 'Sell' rating on LLY.